| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_318bc29db6c3b361e0eae33a0307b39c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C243-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-101
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C243-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-04 |
| filingDate |
2015-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1471d41b1bd290fea8c91e7b0847dd38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc0a95695b3632e6b55d7b1e571ca63c |
| publicationDate |
2016-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2968261-A1 |
| titleOfInvention |
Targeted contrast agents comprising a hydrazide functional group |
| abstract |
Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes a hydrazide functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal- complexable portion of the contrast agent. The portion that is not bound to a metal ion localizes the contrast agent to necrotic tissue in the subject. |
| priorityDate |
2014-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |